[
    [
        {
            "time": "",
            "original_text": "安图生物：公司2020年应收账款较高主要系公司整体服务业务收入增长快",
            "features": {
                "keywords": [
                    "安图生物",
                    "2020年",
                    "应收账款",
                    "服务业务",
                    "收入增长"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技",
                    "医疗服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安图生物：公司2020年应收账款较高主要系公司整体服务业务收入增长快",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "安图生物：2020年度并未发生公司高管单独减持公司股票的情形",
            "features": {
                "keywords": [
                    "安图生物",
                    "2020年度",
                    "高管",
                    "减持",
                    "股票"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "安图生物：2020年度并未发生公司高管单独减持公司股票的情形",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "安图生物：去年毛利率有所下降系因成本增加",
            "features": {
                "keywords": [
                    "安图生物",
                    "去年",
                    "毛利率",
                    "下降",
                    "成本增加"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "安图生物：去年毛利率有所下降系因成本增加",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        }
    ]
]